Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Tatjana Gibbons, an investigator on the ongoing DETECT study, presented results at the World Congress on Endometriosis 2025. The study aims to determine the feasibility of detecting endometriosis using 99mTc-maraciclatide and single-photon emission computed tomography.

Endometriosis Imaging Study

Primary Endpoint Met in the DETECT Endometriosis Imaging Study. 

Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing 99mTc-maraciclatide, an innovative molecular imaging agent, and the Nuffield Department of Women’s and Reproductive Health announce that the primary endpoint has been met in the “Detecting Endometriosis expressed integrins using technetium-99m” (DETECT) Phase II imaging study. 

Dr Tatjana Gibbons from the team running the study at the Nuffield Department of Women’s and Reproductive Health at the University of Oxford, presented the headline data on the award stage at the World Congress on Endometriosis in Sydney. The trial has demonstrated a high correlation between locations of maraciclatide uptake identified on SPECT-CT and laparoscopy across all types of endometriotic lesions, including superficial peritoneal endometriosis, which is not well visualised with existing non-invasive imaging techniques. 

The study is being led by Professor Christian Becker, Co-Director of the Endometriosis CaRe Centre in Oxford, together with Professor Krina Zondervan, Co-Director of the Endometriosis CaRe Centre and Head of Department at the Nuffield Department of Women’s and Reproductive Health, University of Oxford.

Detailed results from the study will be made available later in the year.  

 

Read the full story on the Nuffield Department of Women's & Reproductive Health website.

Similar stories

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Researchers from the Nuffield Department of Primary Care Health Sciences contribute to parliamentary calls for overhaul of obesity care

Research from the Health Behaviors team has informed a series of parliamentary reports calling for urgent action to tackle obesity in England.

Oxford University invites 100,000 people to take part in a major study of plant-based diets

Researchers at the Nuffield Department of Population Health have launched a major new study designed to generate the most up-to-date picture of different diets in the UK, including plant-based diets, and how they affect long-term health and wellbeing.

Look beyond my skin: your psoriasis could help us understand who develops psoriatic arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

Professor Matthew Wood receives BioUK Special Recognition Award 2026

Professor Matthew Wood, Director and Chief Scientific Officer of the Oxford-Harrington Rare Disease Centre (OHC), has received BioUK’s Special Recognition Award 2026 for his contribution to rare disease research, therapeutic development and the wider life sciences sector.

University of Oxford and BIIE launch collaboration in translational immune engineering

Researchers from the Department of Paediatrics at the University of Oxford and the Botnar Institute of Immune Engineering (BIIE) came together in Oxford last week for the inaugural scientific meeting of the new Basel–Oxford Centre for Translational Immune Engineering for Child and Adolescent Health (CTIE).